Floyd-Reising S A, Kelley S G, Hindler J A, Young L S
Diagn Microbiol Infect Dis. 1987 Apr;6(4):301-6. doi: 10.1016/0732-8893(87)90179-9.
The in vitro activity of the quinolone CI-934 was compared with ciprofloxacin, norfloxacin, enoxacin, and vancomycin against 607 Gram-positive and -negative isolates. CI-934 inhibited 90% of the Enterobacteriaceae, Aeromonas hydrophila, and Acinetobacter spp. at 1 microgram/ml. Decreased activity was observed against Pseudomonas aeruginosa. Pseudomonas maltophilia, and other Pseudomonas spp. with CI-934 MIC90 greater than or equal to 8 micrograms/ml. CI-934 activity against Gram-positive organisms exceeded vancomycin and the other quinolones. MIC90 for Streptococcus faecalis, Listeria monocytogenes, and Corynebacterium spp. were less than or equal to 2 micrograms/ml. CI-934 was equally effective against oxacillin-susceptible and -resistant staphylococci with MIC90 of 0.5 micrograms/ml.
将喹诺酮类药物CI - 934与环丙沙星、诺氟沙星、依诺沙星及万古霉素针对607株革兰氏阳性和阴性分离菌株进行了体外活性比较。CI - 934在1微克/毫升浓度时可抑制90%的肠杆菌科细菌、嗜水气单胞菌及不动杆菌属细菌。对铜绿假单胞菌、嗜麦芽窄食单胞菌及其他假单胞菌属细菌的活性降低，CI - 934的MIC90大于或等于8微克/毫升。CI - 934对革兰氏阳性菌的活性超过万古霉素及其他喹诺酮类药物。粪肠球菌、单核细胞增生李斯特菌及棒状杆菌属的MIC90小于或等于2微克/毫升。CI - 934对苯唑西林敏感及耐药葡萄球菌同样有效，MIC90为0.5微克/毫升。
